Today: 7 February 2026
Subscribe
Browse Category

Pharma Industry News 29 December 2025 - 7 January 2026

Crinetics (CRNX) shares jump as $350 million stock sale clears and early PALSONIFY revenue hits

Crinetics (CRNX) shares jump as $350 million stock sale clears and early PALSONIFY revenue hits

New York, Jan 7, 2026, 11:04 EST — Regular session Shares of Crinetics Pharmaceuticals rose about 16% to $53.40 on Wednesday, after the biotech priced a $350 million stock offering and detailed early U.S. launch metrics for its newly approved acromegaly drug. Crinetics said it generated preliminary, unaudited net product revenue of more than $5 million from PALSONIFY in the fourth quarter of 2025, with more than 200 enrollment forms and over 125 unique prescribers by the end of December. It also posted Phase 2 results for atumelnant in congenital adrenal hyperplasia (CAH), reporting a 67% mean reduction in androstenedione
7 January 2026
·····
Ventyx Biosciences stock jumps premarket as Eli Lilly buyout talks fuel takeover buzz

Ventyx Biosciences stock jumps premarket as Eli Lilly buyout talks fuel takeover buzz

New York, Jan 7, 2026, 05:03 EST — Premarket Ventyx Biosciences shares jumped about 66% before the bell on Wednesday after a report that Eli Lilly is in advanced talks to buy the biotech company for more than $1 billion. The stock traded at $16.70 in premarket action, versus a $10.05 regular-session close. Public The move matters because a confirmed deal would lock in a takeover premium for a company whose value has swung sharply on trial timelines and pipeline expectations. It also tests whether big drugmakers are willing to pay up for clinical-stage assets tied to inflammation and obesity-linked
7 January 2026
······
Cipla share price slides after USFDA flags Pharmathen: what the Form 483 says

Cipla share price slides after USFDA flags Pharmathen: what the Form 483 says

Mumbai, Jan 7, 2026, 12:33 IST Shares of Cipla were down 4.6% at 1,460.2 rupees by midday on Wednesday after the U.S. Food and Drug Administration published inspection observations for Pharmathen International S.A., a contract manufacturer linked to the Indian drugmaker’s U.S. supply chain. The Economic Times The disclosure matters because Pharmathen is a key manufacturing partner for Cipla’s lanreotide product in the United States, an area investors track closely for growth and margins. Any compliance overhang at a third-party plant can tighten supply, delay launches and force costly workarounds. Angel One FDA inspectors use a Form 483 to document
7 January 2026
····
Wave Life Sciences stock jumps 17% as obesity gene-silencing race heats up

Wave Life Sciences stock jumps 17% as obesity gene-silencing race heats up

New York, January 6, 2026, 11:28 EST — Regular session Wave Life Sciences Ltd shares (WVE.O) jumped about 17% on Tuesday, extending sharp swings in the obesity drug trade as investors sized up the next set of clinical readouts. The stock was up 17.2% at $17.58 in morning trade on Nasdaq, after moving between $14.15 and $19.49, with about 7.0 million shares traded. The move shows how quickly sentiment can shift in obesity-linked biotechs, where small early-stage updates often drive outsized price action. Investors are hunting for approaches that can cut harmful fat while preserving muscle, a sticking point for
6 January 2026
···
NewAmsterdam Pharma stock slides on insider sale notices — what investors watch next for NAMS

NewAmsterdam Pharma stock slides on insider sale notices — what investors watch next for NAMS

New York, Jan 5, 2026, 15:21 EST — Regular session Shares of NewAmsterdam Pharma Company N.V. fell about 5% to $33.42 in afternoon trading on Monday. The Nasdaq-listed stock hit an intraday low of $32.68 after opening at $35.15. The move followed two Form 144 filings that signaled planned sales by company affiliates. In smaller biotech names, even routine insider activity can sway short-term sentiment when liquidity is thinner. Form 144 is an SEC notice filed before certain holders sell stock under Rule 144, which governs resales of restricted or “control” shares. The filing does not confirm a sale, but
5 January 2026
····
Eli Lilly stock: What to watch before Monday as JPM Healthcare and earnings near

Eli Lilly stock: What to watch before Monday as JPM Healthcare and earnings near

NEW YORK, Jan 4, 2026, 17:22 ET — Market closed Eli Lilly shares rose 0.5% to $1,080.36 at Friday’s close, leaving the stock near the top of its recent range as U.S. markets remained shut over the weekend. Lilly Investor Relations The next catalysts are close. Investors start the week positioning for the J.P. Morgan Healthcare Conference, the industry’s first major investor gathering of the year, where management teams often set the tone for guidance and pipeline priorities. JPMorgan Chase For Lilly, the bar is higher than most. The stock’s run has been powered by demand for its obesity and
4 January 2026
·····
Wave Life Sciences stock tumbles 8.5% in first 2026 session as traders refocus on next WVE-007 readout

Wave Life Sciences stock tumbles 8.5% in first 2026 session as traders refocus on next WVE-007 readout

NEW YORK, January 2, 2026, 14:13 ET — Regular session Wave Life Sciences Ltd shares slid on Friday, giving back part of last month’s obesity-driven run as the biotech sector wobbled in the first U.S. session of 2026. The stock was down about 8.5% at $15.55 as of 2:13 p.m. ET. The retreat matters because Wave has become a high-volatility obesity “story stock,” with investors trying to price the upside of an early-stage program against the risks that come with thin clinical data and heavy funding needs. The shares more than doubled on December 8 after the company posted interim
2 January 2026
·····
Cytokinetics (CYTK) stock closes up 3.5% into year-end as Myqorzo launch nears, insider sale disclosed

Cytokinetics (CYTK) stock closes up 3.5% into year-end as Myqorzo launch nears, insider sale disclosed

NEW YORK, January 1, 2026, 21:17 ET — Market closed Cytokinetics, Incorporated shares ended Wednesday up 3.5% at $63.54, the final U.S. trading session of 2025, after markets closed Thursday for the New Year’s Day holiday. The stock has traded between $29.31 and $70.98 over the past 52 weeks, according to market data. New York Stock Exchange The year-end move matters because Cytokinetics is weeks away from its first full-scale commercial test. Investors have been valuing the biotech on clinical data and regulatory milestones; the next swing factor is execution in the field. In mid-December, the company said the U.S.
2 January 2026
·····
Merck (MRK) stock slips into 2026 as New Year holiday shuts U.S. markets — what investors watch next

Merck (MRK) stock slips into 2026 as New Year holiday shuts U.S. markets — what investors watch next

NEW YORK, January 1, 2026, 14:30 ET — Market closed Merck & Co.’s stock ended the year’s final trading session lower and was little changed in after-hours trading — the session after the 4 p.m. close — with U.S. markets shut on Thursday for New Year’s Day. The shares closed Dec. 31 down 0.75% at $105.26 and last traded at $105.40 after hours. Investing.com+1 The holiday pause comes after Wall Street slid in thin year-end trade on Wednesday, leaving investors to reset positions for 2026 without a fresh U.S. equity session on the holiday. The S&P 500 fell 0.74% on
1 January 2026
·····
Pfizer stock today: PFE edges up after TD Cowen sticks with Hold as investors size up 2026 outlook

Pfizer stock today: PFE edges up after TD Cowen sticks with Hold as investors size up 2026 outlook

NEW YORK, December 30, 2025, 13:50 ET — Regular session Pfizer Inc (NYSE:PFE) shares were up about 0.1% at $25.03 in afternoon trading on Tuesday, after moving between $24.92 and $25.10. TD Cowen reiterated its Hold rating and kept a $30 price target, pointing to negative trends in its model through 2030 despite the stock’s dividend yield near 7%. Investing.com The call lands as investors weigh Pfizer’s latest 2026 targets after the drugmaker projected revenue of $59.5 billion to $62.5 billion next year and adjusted earnings of $2.80 to $3.00 a share. “Adjusted” earnings strip out certain items the company
30 December 2025
·····
SELLAS Life Sciences (SLS) stock jumps on Phase 3 AML trial timing update — what investors watch next

SELLAS Life Sciences (SLS) stock jumps on Phase 3 AML trial timing update — what investors watch next

NEW YORK, December 30, 2025, 01:49 ET — Market closed SELLAS Life Sciences Group Inc (SLS) shares jumped 16.7% on Monday to close at $3.35 after the company updated investors on the timing of a late-stage acute myeloid leukemia (AML) trial. The stock traded between $2.60 and $3.44 and logged about 22.4 million shares, according to StockAnalysis data. StockAnalysis The update matters because REGAL is the company’s main near-term catalyst, and the market is trying to pin down when the final dataset will be ready. In biotech, a change in timing can move shares even when there is no new
30 December 2025
·····
Bristol Myers stock drifts near $55 as year-end trading thins and Fed minutes loom

Bristol Myers stock drifts near $55 as year-end trading thins and Fed minutes loom

NEW YORK, December 28, 2025, 23:31 ET — Market closed Bristol Myers Squibb shares ended Friday slightly lower at $54.64, as the U.S. market headed into the year’s final trading days with few fresh company-specific catalysts. Bristol Myers Squibb That matters now because thin year-end liquidity — lower trading volume around the holidays — can amplify day-to-day swings, even when headlines are scarce. Investors are also adjusting portfolios into 2026, a process that can trigger abrupt sector rotations. Reuters For Bristol Myers, a large-cap drugmaker often traded as a defensive holding, the near-term tape is being shaped more by rates
29 December 2025
·····
1 2 3 4 5 … 9

Stock Market Today

Halma share price: Friday’s lift sets up what investors watch next week

Halma share price: Friday’s lift sets up what investors watch next week

7 February 2026
Halma shares closed up 0.7% at 3,548 pence on Friday, valuing the group at about £13.4 billion. The Bank of England held rates at 3.75% in a split vote, keeping rate-cut speculation in focus. Halma’s next trading update is set for March 12. The FTSE 100 ended the week up 0.6%, lifted by bank stocks.
Diageo share price slips into the weekend as investors eye Feb. 25 results

Diageo share price slips into the weekend as investors eye Feb. 25 results

7 February 2026
Diageo shares closed down 1.48% at 1,760 pence on Friday, trailing a 0.59% gain in the FTSE 100. An updated analyst consensus points to a 2.0% fall in first-half organic net sales ahead of interim results due Feb. 25. Trading volume was light, and the stock remains over 22% below its 52-week high.
National Grid share price: what to know before London reopens after BoE signal

National Grid share price: what to know before London reopens after BoE signal

7 February 2026
National Grid shares closed at 1,285 pence in London on Friday, up 0.23%. The Bank of England held rates at 3.75% after a close vote, signaling possible cuts if inflation falls. National Grid announced a wireless power transmission study with Space Solar and marked five years of IFA2 interconnector operations. Its U.S. ADR ended at $88.06, up $1.17.
BAE Systems share price rises into weekend — what to watch before Monday’s London open

BAE Systems share price rises into weekend — what to watch before Monday’s London open

7 February 2026
BAE Systems shares closed up 1.2% at 1,879 pence on Friday, tracking gains in European defence stocks. The company’s market value stands near £54.8 billion. Investors await BAE’s full-year results on Feb. 18 for updates on cash returns and orders. GXO Logistics renewed and expanded its contract to support BAE’s Type 26 frigate program in Scotland.
Go toTop